PUBLISHER: The Business Research Company | PRODUCT CODE: 1826959
PUBLISHER: The Business Research Company | PRODUCT CODE: 1826959
Oncolytic Adenovirus Global Market Report 2025
Oncolytic adenovirus is a genetically modified virus designed to selectively target and destroy cancer cells while preserving healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which continue attacking the cancer. Additionally, it stimulates the immune system, enhancing the body's anti-tumor response.
The primary types of oncolytic adenoviruses include adenovirus type 5-based oncolytic viruses, adenovirus type 2-based oncolytic viruses, and other variants. Adenovirus type 5-based oncolytic viruses are genetically engineered to selectively infect and destroy cancer cells while sparing normal tissues. These viruses are used in the treatment of melanoma, prostate cancer, breast cancer, ovarian cancer, lung cancer, and other malignancies. End-users include hospitals, cancer research institutes, biotechnology companies, and academic and research institutions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The oncolytic adenovirus market research report is one of a series of new reports from The Business Research Company that provides oncolytic adenovirus market statistics, including the oncolytic adenovirus industry global market size, regional shares, competitors with the oncolytic adenovirus market share, detailed oncolytic adenovirus market segments, market trends, and opportunities, and any further data you may need to thrive in the oncolytic adenovirus industry. This oncolytic adenovirus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The oncolytic adenovirus market size has grown strongly in recent years. It will grow from $122.31 billion in 2024 to $132.49 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increased cancer prevalence, growing demand for targeted cancer therapies, rising R&D funding, improved delivery methods, and regulatory approvals.
The oncolytic adenovirus market size is expected to see strong growth in the next few years. It will grow to $181.71 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to growing cancer prevalence and incidence, expansion of combination therapies, regulatory advancements and approvals, technological advancements in virus engineering, and increased investment in oncology research. Major trends in the forecast period include advancements in viral engineering techniques, advanced drug delivery systems, advancements in tumor targeting precision, advanced immunotherapy combinations, and advancements in patient monitoring and diagnostics.
The forecast of 8.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could slow U.S. immunotherapy advances by inflating prices of viral vector production systems (Belgium) and GMP-grade cell culture media (UK), resulting in delayed clinical trials and higher biomanufacturing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising incidence of cancer is expected to drive the expansion of the oncolytic adenovirus market in the coming years. Cancer is a disease characterized by uncontrolled cell growth and its spread to other parts of the body. Factors such as aging populations, lifestyle choices, environmental exposures, genetic predispositions, and advancements in detection contribute to the increasing number of cancer cases. Oncolytic adenoviruses selectively target and destroy cancer cells, presenting a promising therapeutic approach to addressing this growing health challenge. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported nearly 20 million new cancer cases and 9.7 million deaths worldwide, with projections for 2040 rising to 29.9 million cases and 15.3 million deaths. Additionally, in 2023, the Australian Bureau of Statistics, an Australia-based government agency, reported that 1.8% of Australians had cancer, with males (2.1%) being slightly more affected than females (1.6%), particularly among those aged 75 and older. As a result, the increasing incidence of cancer is fueling growth in the oncolytic adenovirus market.
Companies operating in the oncolytic adenovirus market are focusing on combination therapies such as VCN-01, which integrates oncolytic virotherapy with chemotherapy to enhance tumor targeting and improve therapeutic outcomes. VCN-01 is an oncolytic adenovirus engineered to selectively infect and destroy cancer cells while also increasing the efficacy of chemotherapy. For instance, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) to its lead candidate, VCN-01. This designation applies to VCN-01 in combination with gemcitabine and nab-paclitaxel for treating metastatic pancreatic adenocarcinoma. The oncolytic adenovirus VCN-01 replicates within tumor cells, helping to break down the tumor stroma, a significant barrier to effective cancer treatment.
In March 2022, Synthetic Biologics, Inc., a US-based biotechnology company, acquired VCN Biosciences for an undisclosed sum. This acquisition strengthens its drug development pipeline by incorporating VCN's clinical-stage drug VCN-01 and preclinical candidate VCN-11, both of which are oncolytic adenoviruses designed to target cancers with high unmet medical needs. VCN Biosciences, S.L. (VCN) is a Spain-based biotechnology company specializing in the development of oncolytic adenoviruses for cancer treatment.
Major players in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, and SillaJen Inc.
North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncolytic adenovirus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the oncolytic adenovirus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The oncolytic adenovirus market consists of revenues earned by entities by providing services such as virus engineering and customization, clinical trial management, regulatory consulting, and contract research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncolytic adenovirus market also includes sales of therapies, customized viral vectors, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oncolytic Adenovirus Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on oncolytic adenovirus market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for oncolytic adenovirus ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncolytic adenovirus market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses; Adenovirus Type 2-Based Oncolytic Viruses; Other Virus Types
- 2) By Application: Melanoma; Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Other Applications
- 3) By End-User: Hospitals; Cancer Research Institutes; Biotechnology Companies; Academic And Research Institutes
- Subsegments:
- 1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based; Second-generation Adenovirus Type 5-based; Engineered Adenovirus Type 5-based
- 2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based; Second-generation Adenovirus Type 2-based; Engineered Adenovirus Type 2-based
- 3) By Other Virus Types: Modified Adenovirus Strains; Hybrid Adenovirus Types; Chimeric Adenoviruses
- Companies Mentioned: Amgen Inc.; Targovax ASA; CG Oncology Inc.; Replimune Group Inc.; Imugene Limited; Oncorus Inc.; PsiOxus Therapeutics Ltd.; Vyriad Inc.; Transgene SA; Valo Therapeutics Oy; EpicentRx Inc.; DNAtrix Inc.; Shanghai Sunway Biotech Co. Ltd.; TILT Biotherapeutics Ltd.; Oncolys BioPharma Inc.; Lokon Pharma AB; GeneMedicine Co. Ltd.; Akamis Bio Ltd.; Genelux Corporation; SillaJen Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Oncolytic Adenovirus Market Characteristics
3. Oncolytic Adenovirus Market Trends And Strategies
4. Oncolytic Adenovirus Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Oncolytic Adenovirus Growth Analysis And Strategic Analysis Framework
- 5.1. Global Oncolytic Adenovirus PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Oncolytic Adenovirus Market Growth Rate Analysis
- 5.4. Global Oncolytic Adenovirus Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Oncolytic Adenovirus Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Oncolytic Adenovirus Total Addressable Market (TAM)
6. Oncolytic Adenovirus Market Segmentation
- 6.1. Global Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Adenovirus Type 5-Based Oncolytic Viruses
- Adenovirus Type 2-Based Oncolytic Viruses
- Other Virus Types
- 6.2. Global Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Melanoma
- Prostate Cancer
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Other Applications
- 6.3. Global Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Cancer Research Institutes
- Biotechnology Companies
- Academic And Research Institutes
- 6.4. Global Oncolytic Adenovirus Market, Sub-Segmentation Of Adenovirus Type 5-Based Oncolytic Viruses, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- First-generation Adenovirus Type 5-based
- Second-generation Adenovirus Type 5-based
- Engineered Adenovirus Type 5-based
- 6.5. Global Oncolytic Adenovirus Market, Sub-Segmentation Of Adenovirus Type 2-Based Oncolytic Viruses, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- First-generation Adenovirus Type 2-based
- Second-generation Adenovirus Type 2-based
- Engineered Adenovirus Type 2-based
- 6.6. Global Oncolytic Adenovirus Market, Sub-Segmentation Of Other Virus Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Modified Adenovirus Strains
- Hybrid Adenovirus Types
- Chimeric Adenoviruses
7. Oncolytic Adenovirus Market Regional And Country Analysis
- 7.1. Global Oncolytic Adenovirus Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Oncolytic Adenovirus Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Oncolytic Adenovirus Market
- 8.1. Asia-Pacific Oncolytic Adenovirus Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Oncolytic Adenovirus Market
- 9.1. China Oncolytic Adenovirus Market Overview
- 9.2. China Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Oncolytic Adenovirus Market
- 10.1. India Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Oncolytic Adenovirus Market
- 11.1. Japan Oncolytic Adenovirus Market Overview
- 11.2. Japan Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Oncolytic Adenovirus Market
- 12.1. Australia Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Oncolytic Adenovirus Market
- 13.1. Indonesia Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Oncolytic Adenovirus Market
- 14.1. South Korea Oncolytic Adenovirus Market Overview
- 14.2. South Korea Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Oncolytic Adenovirus Market
- 15.1. Western Europe Oncolytic Adenovirus Market Overview
- 15.2. Western Europe Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Oncolytic Adenovirus Market
- 16.1. UK Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Oncolytic Adenovirus Market
- 17.1. Germany Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Oncolytic Adenovirus Market
- 18.1. France Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Oncolytic Adenovirus Market
- 19.1. Italy Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Oncolytic Adenovirus Market
- 20.1. Spain Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Oncolytic Adenovirus Market
- 21.1. Eastern Europe Oncolytic Adenovirus Market Overview
- 21.2. Eastern Europe Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Oncolytic Adenovirus Market
- 22.1. Russia Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Oncolytic Adenovirus Market
- 23.1. North America Oncolytic Adenovirus Market Overview
- 23.2. North America Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Oncolytic Adenovirus Market
- 24.1. USA Oncolytic Adenovirus Market Overview
- 24.2. USA Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Oncolytic Adenovirus Market
- 25.1. Canada Oncolytic Adenovirus Market Overview
- 25.2. Canada Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Oncolytic Adenovirus Market
- 26.1. South America Oncolytic Adenovirus Market Overview
- 26.2. South America Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Oncolytic Adenovirus Market
- 27.1. Brazil Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Oncolytic Adenovirus Market
- 28.1. Middle East Oncolytic Adenovirus Market Overview
- 28.2. Middle East Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Oncolytic Adenovirus Market
- 29.1. Africa Oncolytic Adenovirus Market Overview
- 29.2. Africa Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Oncolytic Adenovirus Market Competitive Landscape And Company Profiles
- 30.1. Oncolytic Adenovirus Market Competitive Landscape
- 30.2. Oncolytic Adenovirus Market Company Profiles
- 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Targovax ASA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. CG Oncology Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Replimune Group Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Imugene Limited Overview, Products and Services, Strategy and Financial Analysis
31. Oncolytic Adenovirus Market Other Major And Innovative Companies
- 31.1. Oncorus Inc.
- 31.2. PsiOxus Therapeutics Ltd.
- 31.3. Vyriad Inc.
- 31.4. Transgene SA
- 31.5. Valo Therapeutics Oy
- 31.6. EpicentRx Inc.
- 31.7. DNAtrix Inc.
- 31.8. Shanghai Sunway Biotech Co. Ltd.
- 31.9. TILT Biotherapeutics Ltd.
- 31.10. Oncolys BioPharma Inc.
- 31.11. Lokon Pharma AB
- 31.12. GeneMedicine Co. Ltd.
- 31.13. Akamis Bio Ltd.
- 31.14. Genelux Corporation
- 31.15. SillaJen Inc.
32. Global Oncolytic Adenovirus Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Oncolytic Adenovirus Market
34. Recent Developments In The Oncolytic Adenovirus Market
35. Oncolytic Adenovirus Market High Potential Countries, Segments and Strategies
- 35.1 Oncolytic Adenovirus Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Oncolytic Adenovirus Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Oncolytic Adenovirus Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
